AWARDDEFINITIVE CONTRACTOther than small business
Definitive contract 75F40121C00194ZATA PHARMACEUTICALS, INC.
Overview
Award facts
- Net obligations
- $6.69M
- $6,692,768of $6.69M potential value
- Outlays (paid to date)
- $6.65M
- $6.65M paid of $6.69M obligated$6,648,852
- Period of performance
- Sep 27, 2021 to Sep 26, 2023
- Ended
- Modifications
- 7
- Latest action Aug 25, 2026
- Contract type
- Definitive contract
- PIID 75F40121C00194
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
DEVELOPMENT AND MAINTENANCE OF FDA-ARGOS 2 UNIVERSAL CLOSED SYSTEMS FOR PATHOGEN REDUCTION IN DONATED WHOLE BLOOD UNITS
Dates and value
- Award date
- Signed on Sep 27, 2021
- Potential end of performance
- Mar 26, 2025
- Current value
- $6,692,768Base and exercised options
- Potential value (if all options are exercised)
- $6,692,768
Obligations by fiscal year of action
- FY2026: -$5,863,963 (de-obligation)
- FY2023: $5,476,220
- FY2022: $4,785,967
- FY2021: $2,294,544
Total across 4 fiscal years: $6,692,768
Net de-obligation in that fiscal year (obligations withdrawn).
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Aug 25, 2026. View on USAspending · Recipient on SAM.gov
Recipient
LocationWORCESTER, MA
UEILM1CSJF7LLS6
CAGE code62U84
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeCorporate not tax exempt
Parent companyZATA PHARMACEUTICALS INC.
Business types and certifications
For-profit organizationCorporation (not tax-exempt)
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded from
- BiologicsProgram activities075-0600Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Silver Spring, Montgomery County, Maryland 20993-0001
- Congressional district (place of performance)
- MD-08As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AN11HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Cost no feeS
- Offers received
- 10
Solicitation and notices
- Solicitation ID
- FDABAA-21-00123
- Solicitation date
- Sep 27, 2021
- Notices
- Solicitation posted May 25, 2021
- Solicitation posted May 25, 2021
- Solicitation posted Jan 28, 2021
- Solicitation posted Nov 20, 2020
Contract details
- Subcontracting plan
- Plan not requiredB
- Cost Accounting Standards clause
- Yes - CAS clause includedY
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- Yes - service where PBA is used.Y
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 27, 2021Base obligation at award: $2,294,544
- Latest action
- Aug 25, 2026 — CloseoutModification P00007; obligation change -$5,863,963; administrative: no change in scope or value
- Latest substantive action
- Aug 29, 2023 — Option exercisedModification P00005; obligation change +$5,476,220
- Actions by type
- Base award1
- Other administrative action5
- Option exercised1
- Closeout1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- -$5,863,963
- Latest action: change in base and all options
- -$13,038,705
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7524
- Contracting office code
- 75F401
- Transactions recorded under this award key
- 8
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7524
- Funding office code
- 75F401
- Treasury accounts
- 075-2021/2021-0600-000
- 075-2022/2022-0600-000
- 075-2023/2023-0600-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression